Carfilzomib(CFZ) is a tetrapeptide epoxyketone and a selective proteasome inhibitor. It is a second-generation proteasome inhibitor that is approved for the treatment of relapsed or refractory multiple myeloma.it is sold under the brand name Kyprolis.

Carfilzomib injection is used alone to treat relapsed or refractory multiple myeloma (a type of bone marrow cancer) in patients who have received one or more previous treatments. it is also used together with other medicines such as dexamethasone,daratumumab,lenalidomide,hyaluronidase to treat relapsed or refractory multiple myeloma in patients who have received 1 to 3 previous treatments. including treatment with bortezomib and an immunomodulatory therapy.